NAD+ Is Everywhere. The Science Is More Complicated Than Your Feed Suggests.

As NAD+ injections and IV drips trend from TikTok to the Kardashians, the science of longevity remains a work in progress. Explore the benefits, side effects, and the debate between oral precursors ...
ascopubs.org

Subcutaneous Immunotherapy in Cancer: Where We Are Now, What It Changes, and What to Watch Next

Subcutaneous (SC) formulations of monoclonal antibodies are rapidly transforming the delivery of cancer immunotherapy. Designed to replace or complement intravenous (IV) administration, SC delivery ...
FiercePharma

With FDA approval, Roche's blood cancer bispecific Lunsumio goes subcutaneous

Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio amid competition among CD20xCD3 bispecific antibodies. The FDA has approved ...
WebMD

FDA Approves Rybrevant Faspro: An Under-the-Skin Injection for Use in Combination With Lazcluze for EGFR-Mutated Lung Cancer

Rybrevant Faspro is a new under-the-skin (subcutaneous) injection form of the cancer medicine Rybrevant (amivantamab). The FDA has now approved it in combination with another medicine called ...
ascopubs.org

Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary ...

Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium Subcutaneous amivantamab-lazertinib demonstrated noninferior ...
Monthly Prescribing Reference

FDA Approves Omvoh Single-Injection Maintenance Regimen for Ulcerative Colitis

According to Lilly, the single-injection, citrate-free, maintenance dose will be available in the US as a prefilled pen or prefilled syringe in early 2026. The Food and Drug Administration (FDA) has ...
MedPage Today

Blockbuster Cancer Drug Can Now Be Administered More Easily

The FDA approved a subcutaneous formulation of the blockbuster cancer drug pembrolizumab (Keytruda Qlex) for use across the drug's numerous solid tumors indications. The new formulation combines ...
FiercePharma

Merck scores FDA approval for subcutaneous Keytruda, securing potential blockbuster protection

The FDA has approved Merck & Co.’s under-the-skin version of Keytruda, reducing treatment time burden for patients while granting the world’s bestselling drug potential blockbuster revenue protection.
Healio

FDA approves Leqembi at-home subcutaneous injection in early Alzheimer’s

Please provide your email address to receive an email when new articles are posted on . Leqembi Iqlik is the first approved in-home anti-amyloid injectable for early Alzheimer’s disease. Patients ...
Medscape

FDA OKs Subcutaneous Lecanemab Maintenance Dosing for Early AD

The FDA has approved a subcutaneous formulation of lecanemab (Leqembi Iqlik, Eisai/Biogen) for maintenance dosing in patients with Alzheimer’s disease (AD) with mild cognitive impairment (MCI) or mild ...
McKnight's Long-Term Care News

FDA OKs subcutaneous lecanemab injection for maintenance dosing for early Alzheimer’s

The US Food and Drug Administration (FDA) has approved the biologics license application for a subcutaneous formulation of lecanemab (Leqembi Iqlik) for weekly maintenance dosing to treat Alzheimer’s ...